Clinical features and outcomes of cytomegalovirus retinitis after transplantation

A. J. Eid, S. J. Bakri, S. Kijpittayarit, Raymund R Razonable

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection of the retina is a rarely encountered end-organ disease after transplantation. In order to describe the clinical characteristics and outcomes of CMV retinitis after hematopoietic stem cell and solid organ transplantation, we performed a retrospective review of all cases of CMV retinitis at the Mayo Clinic (Rochester, Minnesota) during 1990-2004. During this 15-year period, CMV retinitis was diagnosed in 14 eyes of 9 patients who had received kidney (n=5), liver (n=2), heart (n=1), and autologous hematopoietic stem cell transplant (n=1). The mean age of the patients was 58 (standard deviation±11) years; 6 were male. The median time to diagnosis of CMV retinitis was 9 months (range, 4 months to 13 years) after transplantation. Four (44%) patients had concomitant pneumonitis or hepatitis. Five (55%) patients had bilateral retinitis. Retinal involvement was ≤10% in 8 eyes, >10% but ≤50% in 4 eyes, and >50% in 2 eyes. All patients received induction therapy with intravenous ganciclovir (n=8) or foscarnet (n=1) for a median of 43 days (range, 14-100 days) followed by maintenance therapy with intravenous or oral ganciclovir for a median of 88 days (range, 36-943 days) in 6 (67%) patients. One patient developed bilateral immune recovery uveitis during treatment, and later on progressed to develop rhegmatogenous retinal detachment. During the mean follow-up period of 20 months, visual acuity improved in 4 (28.5%), was stable in 4 (28.5%), and worsened in 6 (43%) eyes. CMV retinitis recurred in 2 patients. In conclusion, CMV retinitis is a rare, progressive, and highly morbid infectious complication of transplantation. The severity of clinical disease at the time of diagnosis may predict poor outcome. Hence, early intervention may be crucial to prevent its progression to irreversible visual loss.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalTransplant Infectious Disease
Volume10
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Cytomegalovirus Retinitis
Transplantation
Ganciclovir
Hematopoietic Stem Cells
Foscarnet
Retinitis
Uveitis
Cytomegalovirus Infections
Organ Transplantation
Retinal Detachment
Hepatitis
Visual Acuity
Retina
Pneumonia
Therapeutics
Transplants
Kidney
Liver

Keywords

  • Bone marrow transplant
  • Cytomegalovirus
  • Ganciclovir
  • Immunosuppression
  • Kidney transplantation
  • Outcomes
  • Retinitis
  • Solid organ transplant
  • Transplantation

ASJC Scopus subject areas

  • Transplantation
  • Microbiology (medical)
  • Immunology

Cite this

Clinical features and outcomes of cytomegalovirus retinitis after transplantation. / Eid, A. J.; Bakri, S. J.; Kijpittayarit, S.; Razonable, Raymund R.

In: Transplant Infectious Disease, Vol. 10, No. 1, 02.2008, p. 13-18.

Research output: Contribution to journalArticle

Eid, A. J. ; Bakri, S. J. ; Kijpittayarit, S. ; Razonable, Raymund R. / Clinical features and outcomes of cytomegalovirus retinitis after transplantation. In: Transplant Infectious Disease. 2008 ; Vol. 10, No. 1. pp. 13-18.
@article{b50d0a731cce421a85b1b63aeae5a597,
title = "Clinical features and outcomes of cytomegalovirus retinitis after transplantation",
abstract = "Cytomegalovirus (CMV) infection of the retina is a rarely encountered end-organ disease after transplantation. In order to describe the clinical characteristics and outcomes of CMV retinitis after hematopoietic stem cell and solid organ transplantation, we performed a retrospective review of all cases of CMV retinitis at the Mayo Clinic (Rochester, Minnesota) during 1990-2004. During this 15-year period, CMV retinitis was diagnosed in 14 eyes of 9 patients who had received kidney (n=5), liver (n=2), heart (n=1), and autologous hematopoietic stem cell transplant (n=1). The mean age of the patients was 58 (standard deviation±11) years; 6 were male. The median time to diagnosis of CMV retinitis was 9 months (range, 4 months to 13 years) after transplantation. Four (44{\%}) patients had concomitant pneumonitis or hepatitis. Five (55{\%}) patients had bilateral retinitis. Retinal involvement was ≤10{\%} in 8 eyes, >10{\%} but ≤50{\%} in 4 eyes, and >50{\%} in 2 eyes. All patients received induction therapy with intravenous ganciclovir (n=8) or foscarnet (n=1) for a median of 43 days (range, 14-100 days) followed by maintenance therapy with intravenous or oral ganciclovir for a median of 88 days (range, 36-943 days) in 6 (67{\%}) patients. One patient developed bilateral immune recovery uveitis during treatment, and later on progressed to develop rhegmatogenous retinal detachment. During the mean follow-up period of 20 months, visual acuity improved in 4 (28.5{\%}), was stable in 4 (28.5{\%}), and worsened in 6 (43{\%}) eyes. CMV retinitis recurred in 2 patients. In conclusion, CMV retinitis is a rare, progressive, and highly morbid infectious complication of transplantation. The severity of clinical disease at the time of diagnosis may predict poor outcome. Hence, early intervention may be crucial to prevent its progression to irreversible visual loss.",
keywords = "Bone marrow transplant, Cytomegalovirus, Ganciclovir, Immunosuppression, Kidney transplantation, Outcomes, Retinitis, Solid organ transplant, Transplantation",
author = "Eid, {A. J.} and Bakri, {S. J.} and S. Kijpittayarit and Razonable, {Raymund R}",
year = "2008",
month = "2",
doi = "10.1111/j.1399-3062.2007.00241.x",
language = "English (US)",
volume = "10",
pages = "13--18",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical features and outcomes of cytomegalovirus retinitis after transplantation

AU - Eid, A. J.

AU - Bakri, S. J.

AU - Kijpittayarit, S.

AU - Razonable, Raymund R

PY - 2008/2

Y1 - 2008/2

N2 - Cytomegalovirus (CMV) infection of the retina is a rarely encountered end-organ disease after transplantation. In order to describe the clinical characteristics and outcomes of CMV retinitis after hematopoietic stem cell and solid organ transplantation, we performed a retrospective review of all cases of CMV retinitis at the Mayo Clinic (Rochester, Minnesota) during 1990-2004. During this 15-year period, CMV retinitis was diagnosed in 14 eyes of 9 patients who had received kidney (n=5), liver (n=2), heart (n=1), and autologous hematopoietic stem cell transplant (n=1). The mean age of the patients was 58 (standard deviation±11) years; 6 were male. The median time to diagnosis of CMV retinitis was 9 months (range, 4 months to 13 years) after transplantation. Four (44%) patients had concomitant pneumonitis or hepatitis. Five (55%) patients had bilateral retinitis. Retinal involvement was ≤10% in 8 eyes, >10% but ≤50% in 4 eyes, and >50% in 2 eyes. All patients received induction therapy with intravenous ganciclovir (n=8) or foscarnet (n=1) for a median of 43 days (range, 14-100 days) followed by maintenance therapy with intravenous or oral ganciclovir for a median of 88 days (range, 36-943 days) in 6 (67%) patients. One patient developed bilateral immune recovery uveitis during treatment, and later on progressed to develop rhegmatogenous retinal detachment. During the mean follow-up period of 20 months, visual acuity improved in 4 (28.5%), was stable in 4 (28.5%), and worsened in 6 (43%) eyes. CMV retinitis recurred in 2 patients. In conclusion, CMV retinitis is a rare, progressive, and highly morbid infectious complication of transplantation. The severity of clinical disease at the time of diagnosis may predict poor outcome. Hence, early intervention may be crucial to prevent its progression to irreversible visual loss.

AB - Cytomegalovirus (CMV) infection of the retina is a rarely encountered end-organ disease after transplantation. In order to describe the clinical characteristics and outcomes of CMV retinitis after hematopoietic stem cell and solid organ transplantation, we performed a retrospective review of all cases of CMV retinitis at the Mayo Clinic (Rochester, Minnesota) during 1990-2004. During this 15-year period, CMV retinitis was diagnosed in 14 eyes of 9 patients who had received kidney (n=5), liver (n=2), heart (n=1), and autologous hematopoietic stem cell transplant (n=1). The mean age of the patients was 58 (standard deviation±11) years; 6 were male. The median time to diagnosis of CMV retinitis was 9 months (range, 4 months to 13 years) after transplantation. Four (44%) patients had concomitant pneumonitis or hepatitis. Five (55%) patients had bilateral retinitis. Retinal involvement was ≤10% in 8 eyes, >10% but ≤50% in 4 eyes, and >50% in 2 eyes. All patients received induction therapy with intravenous ganciclovir (n=8) or foscarnet (n=1) for a median of 43 days (range, 14-100 days) followed by maintenance therapy with intravenous or oral ganciclovir for a median of 88 days (range, 36-943 days) in 6 (67%) patients. One patient developed bilateral immune recovery uveitis during treatment, and later on progressed to develop rhegmatogenous retinal detachment. During the mean follow-up period of 20 months, visual acuity improved in 4 (28.5%), was stable in 4 (28.5%), and worsened in 6 (43%) eyes. CMV retinitis recurred in 2 patients. In conclusion, CMV retinitis is a rare, progressive, and highly morbid infectious complication of transplantation. The severity of clinical disease at the time of diagnosis may predict poor outcome. Hence, early intervention may be crucial to prevent its progression to irreversible visual loss.

KW - Bone marrow transplant

KW - Cytomegalovirus

KW - Ganciclovir

KW - Immunosuppression

KW - Kidney transplantation

KW - Outcomes

KW - Retinitis

KW - Solid organ transplant

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=38649114995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649114995&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2007.00241.x

DO - 10.1111/j.1399-3062.2007.00241.x

M3 - Article

C2 - 17511815

AN - SCOPUS:38649114995

VL - 10

SP - 13

EP - 18

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 1

ER -